ENGN
enGene Therapeutics Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No N-PORT holders.
Largest filed tie
0
filed ties
—
No thesis.
enGene Therapeutics Inc.
1.60
+0.15 · +10.06%
post 1.58 −1.00%
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | BML Capital ManagementBML | $11.5M | 17.10% | new | |
| 2 | SirenSiren | $10.8M | 16.04% | new | |
| 3 | Perceptive AdvisorsPerceptive | $8.3M | 12.36% | new | |
| 4 | Ameriprise FinancialAmeriprise Financial | $4.6M | 6.86% | new | |
| 5 | Nextech InvestNextech Invest | $4.0M | 5.96% | new | |
| 6 | ADAR1 Capital ManagementADAR1 | $3.6M | 5.40% | new | |
| 7 | Vestal Point CapitalVestal Point Capital | $2.9M | 4.27% | new | |
| 8 | Acorn Capital AdvisorsAcorn Capital | $2.2M | 3.26% | new | |
| 9 | Peapod Lane CapitalPeapod Lane Capital | $1.9M | 2.83% | new | |
| 10 | Balyasny Asset ManagementBalyasny | $1.7M | 2.58% | new | |
| 11 | Millennium ManagementMillennium | $1.7M | 2.48% | new | |
| 12 | Renaissance TechnologiesRenaissance Technologies | $1.4M | 2.13% | new | |
| 13 | Citadel AdvisorsCitadel | $1.4M | 2.00% | new | |
| 14 | Affinity Asset AdvisorsAffinity Asset | $1.0M | 1.54% | new | |
| 15 | UBS GroupUBS | $880,721 | 1.31% | new | |
| 16 | Eversept PartnersEversept Partners | $812,380 | 1.20% | new | |
| 17 | Kynam Capital ManagementKynam | $792,089 | 1.17% | new | |
| 18 | Jane Street GroupJane Street | $789,328 | 1.17% | new | |
| 19 | Seven Fleet Capital ManagementSeven Fleet | $711,142 | 1.05% | new | |
| 20 | Susquehanna International GroupSusquehanna International | $691,083 | 1.02% | new | |
| 21 | Rangeley CapitalRangeley Capital | $527,826 | 0.78% | new | |
| 22 | BarclaysBarclays | $488,751 | 0.72% | new | |
| 23 | Kennedy Capital ManagementKennedy | $464,912 | 0.69% | new | |
| 24 | Woodline PartnersWoodline Partners | $432,500 | 0.64% | new | |
| 25 | Quadrature CapitalQuadrature Capital | $413,531 | 0.61% | new |
56 managers report $67.5M of enGene Therapeutics on form 13F for the quarter ended Jun 30 '26. 12 of them hold 80% of it; BML is largest at 17.10%.
Expected move
No implied move.